Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBLED foliglurax phase IIa trial in Parkinson's disease with wearing-off and levodopa-induced dyskinesia
2017-000135-14Phase 2Completed
- Sponsor
- Prexton Therapeutics
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of foliglurax in Parkinson's disease (PD) (3 arms), sponsored by Prexton Therapeutics. Primary endpoint: Change in daily awake OFF time. Started Mar 2017; status: completed.
02
Drugs
foliglurax
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2017-000135-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000135-14.